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Volume 51, Number 11S Abstracts 19SResults: For ENDO, 36 chimney stents (1.7/patient),
8—SMA and renal, 7—bilateral renals, 5—single renal,
1—SMA, were successfully placed in 37 branches (97%); 1
renal occluded from loss of guidewire. For OPEN, there
were 15 tube and 6 aortoiliac grafts. Perioperative data are
shown in Table. Kaplan-Meier patency at 1 and 6 months
was 97.3%. There was one type 1a endoleak at 30-days.
Despite a lower preoperative eGFR in the ENDO group
(52 vs 60 mL/min/1.73m2, p  0.017) the median post-
operative change was similar (-0.5 vs 0 mL/min/1.73m2,
p  0.841); 2 OPEN, but no ENDO, patients required
dialysis.
Conclusions: Chimney technique may be a viable
option for repair of suprarenal aneurysms and an “off-
the-shelf” alternative to custom fenestrated/branched
endografts. Perioperative benefits of endovascular repair
are maintained with preservation of end organ function.
Late stent patency and proximal fixation remains to be
determined.
TABLE ENDO OPEN P
Proc Time (min) 235 213 0.65
EBL (ml) 350 1500 0.001
PRBC transfusion (units) 1 3 0.007
ICU stay (days) 1 4 0.001
Total LOS (days) 5 10 0.021
Mortality (n) 1 (4.8%) 1 (4.8%) 1.0
Adverse Events (n) 29 61
All (n/patient) 1.4 2.9 0.75
Severe (n/patient) 0.3 0.7 0.60
Author Disclosures: A. W. Beck: Nothing to disclose;
K. J. Bruen: Nothing to disclose; R. J. Feezor: Nothing to
disclose; T. S. Huber: Nothing to disclose; W. Lee: Noth-
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Objectives: The Zenith Renu AAA Ancillary Graft,
which gained FDA approval in June 2005, provides active
proximal fixation for treatment of pre-existing endografts
with failed or failing proximal fixation or seal. The purpose
of this study is to evaluate the midterm outcome of treat-
ment with this device.
Methods: From 09/2005 to 11/2006, a prospective,
nonrandomized, post-market registry was implemented,
collecting experience from 151 cases (89 converters and 62
main body extensions) at 95 institutions. Preoperative in-
dications, procedural and post-implantation outcomes
were analyzed. Technical success and clinical success were
determined as defined by the SVS reporting standards.Results: Patients were predominantly male (87%)
with mean age of 77 years. The interval between the
original endograft implantation to Renu treatment was
43.4  18.7 months. The indications for treatment were
endoleak (n  108), migration (n  136), or both (n 
94). Technical success was 98% with 2 cases of intraop-
erative conversion and 1 persistent type IA endoleak.
The mean follow-up for the cohort was 18.5  12.7
months (range 0-48). Overall, 23 patients had treatment
failures which included at least one of the following: 8
type I/III endoleaks, 1 migration, 7 aneurysm enlarge-
ment 5mm, 3 aneurysm ruptures, 8 conversions (with
6 after 30 days), and 5 identified procedure-related
deaths. Overall, the clinical success for the entire cohort
during the follow-up period was 84.7%.
Conclusions: The post-market registry data confirms
that the Zenith Renu AAA Ancillary Graft can be used to
treat failed endovascular repairs from proximal attachment
failures. However, this is associated with a high rate of
midterm failure. While we can salvage failed endovascular
repairs, these results emphasize the importance of patient
and device selection during initial endovascular aneurysm
repair. In this challenging population with endovascular
graft failure, surgical conversion should be considered for
those that are medically fit for open repair.
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fees or other remuneration (payment); J. Jim: Nothing to
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Objectives: Historically, women have higher mortality
rates after AAA repair than men. Although endovascular
repair (EVAR) has improved these rates, how gender affects
long-term survival after AAA repair is unknown. We ana-
lyzed survival in matched cohorts after EVAR and open
(OAR) repair for elective (eAAA) and ruptured (rAAA)
abdominal aortic aneurysm.
Methods: From the Medicare Beneficiary Database,
we compiled a cohort of patients who underwent OAR or
EVAR repair for either eAAA (n 214, 802) or rAAA (n
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demographics, comorbidities, institution and operator’s
experience using propensity method. Long-term survival
of the matched groups was compared by Kaplan Meier
analysis.
Results: For eAAAs, perioperative mortality was signif-
icantly lower among EVAR recipients compared to OAR
recipients for both men and women (1.56% vs 3.86% for
men and 2.84% vs 5.36% for women, p  0.0001). One
difference, however, is that the EVAR survival benefit was
sustained in women but disappeared in men after 1.5 years.
Relatedly, the survival benefit of men over women after
elective EVAR disappeared after 1.5 years. For rAAAs,
30-daymortality was significantly lower amongmale EVAR
recipients compared OAR recipients (37.70% vs 47.62%,
p  0.0001) but this was not the case for women (46.99%
vs 47.81%, p0.05). Three-year survival was significantly
higher for men who received EVAR compared to OAR
(p  0.0053), but this treatment modality difference was
not seen among women. Moreover, survival was substan-
tially higher for men after emergent EVAR (p  0.0036).
Conclusions: Gender disparity is evident from long-
term outcomes after AAA repair. This is especially the case
for rAAA, where the long-term outcome for women was
significantly worse than for men and where the less invasive
treatment modality of EVAR did not appear to benefit
women as it did for men. These associations require further
study to isolate specific risk factors that would be potential
targets for improving AAA management.
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Objectives: To analyze outcomes of bilateral percuta-
neous (PC) vs femoral cutdown (FC) access for endovas-
cular repair (EVAR) of AAA.
Methods: We used NSQIP 2005-07. We selected pa-
tients, using ICD-9 & CPT codes, with intact (iAAA)
aneurysm, undergoing bifurcated EVAR. Cohorts were
defined by presence/absence of CPT for FC. We excluded
femoral-femoral bypass & brachial access patients.
Results: We isolated 5086 repairs. PC use increased
over time (36 - 46%). Females underwent FC more often
(61 vs 39%; p 0.05). Comorbidities were similar between
groups, except for ASA class, which was higher with PC
(3.14 vs 3.07; p  0.01). PC patients received general
anesthesia more often (82 vs 78%; p  0.01). Mean dura-tion of anesthesia (3.5 vs 3.7 hrs) and operative time (2.3 vs
2.5 hrs) were lower with PC (all p  0.01). 30 d mortality
(1.2% PC vs 0.9% FC) aggregate morbidity (9.5% PC vs
8.6% FC) and intraoperative blood transfusions (11% PC vs
10% FC; p 0.23) were similar between groups. Although
uncommon,MI (0.3 vs 0.1%; p 0.05), pneumonia (1.6 vs
1.0%; p  0.05) and DVT (1.1 vs 0.3%; p  0.01) were
higher with PC without a significant decrease in infections
(1.6 vs 2.4%; p 0.16) or length of stay (mean: 2.6 vs 3.0d;
p  0.47). Female sex, was independently predictive of
worse morbidity (OR: 1.7[1.3, 2.1]) and mortality (OR:
1.9[1.0, 3.6]).
Conclusions: Percutaneous access is being performed
increasingly with no benefit in rates of wound infection or
30-day mortality. Contrary to previous reports, PC is asso-
ciated with higher rates of MI, pneumonia, DVT as well as
greater use of general anesthesia, indicating that the poten-
tial benefit of decreased sedation is not being exploited.
Better selection criteria are needed tomaximize the benefits
of percutaneous access.
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Objectives: Endovascular interventions have largely
replaced surgical treatment of aortoiliac occlusive disease.
This review reports on current indications and outcomes of
surgical bypass of AIOD.
Methods: Retrospective review of all patients treated
for AIOD. Kaplan-Meier and logistic regression analyses of
all variables were applied.
Results: 2200 patients underwent interventions for
AIOD between 2000-08: only 205 (9.3%) had a surgical
bypass: 142 aortofemoral and 63 axillofemoral.Mean age was
64.4 10.8 (54%males) (Table 1). Mean FUwas 25.3mths.
Indications were claudication (25%) or critical limb ischemia
(75%, 15% acute ischemia). All but nine patients had bilateral
iliac occlusions (61) aortic occlusion to the renals (57) or both
(56). Prior endovascular interventions were present in 36%:
failed iliac angioplasty/stent in 29% and a failed recanalization
in 7%. The mean ABI increased from 0.32 0.20 to 0.85
0.22 post op. Patients with an ax-fem bypass had more co-
morbidities and a highermortality (HR 7.9, p 0.001). At
